Literature DB >> 29752941

Met receptor inhibitor SU11274 localizes in the endoplasmic reticulum.

Edwin J Wiest1, Heather Jensen Smith2, Michael A Hollingsworth3.   

Abstract

We discovered that SU11274, a class I c-Met inhibitor, fluoresces when excited by 488 nm laser light and showed rapid specific accumulation in distinct subcellular compartments. Given that SU11274 reduces cancer cell viability, we exploited these newly identified spectral properties to determine SU11274 intracellular distribution and accumulation in human pancreatic cancer cells. The aim of the studies reported here was to identify organelle(s) to which SU11274 is trafficked. We conclude that SU11274 rapidly and predominantly accumulates in the endoplasmic reticulum.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  Endoplasmic reticulum; SU11274; Sulfonylurea receptor; Unfolded protein response

Mesh:

Substances:

Year:  2018        PMID: 29752941      PMCID: PMC9019716          DOI: 10.1016/j.bbrc.2018.05.034

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.322


  14 in total

Review 1.  Visiting the ER: the endoplasmic reticulum as a target for therapeutics in traffic related diseases.

Authors:  Meir Aridor
Journal:  Adv Drug Deliv Rev       Date:  2007-06-21       Impact factor: 15.470

2.  Hepatocyte growth factor plays a key role in insulin resistance-associated compensatory mechanisms.

Authors:  Tiago G Araújo; Alexandre G Oliveira; Bruno M Carvalho; Dioze Guadagnini; André O P Protzek; Jose B C Carvalheira; Antonio C Boschero; Mario J A Saad
Journal:  Endocrinology       Date:  2012-09-28       Impact factor: 4.736

3.  Overexpression of MUC1 reconfigures the binding properties of tumor cells.

Authors:  K M McDermott; P R Crocker; A Harris; M D Burdick; Y Hinoda; T Hayashi; K Imai; M A Hollingsworth
Journal:  Int J Cancer       Date:  2001-12-15       Impact factor: 7.396

4.  Targeting IRE1 with small molecules counteracts progression of atherosclerosis.

Authors:  Ozlem Tufanli; Pelin Telkoparan Akillilar; Diego Acosta-Alvear; Begum Kocaturk; Umut Inci Onat; Syed Muhammad Hamid; Ismail Çimen; Peter Walter; Christian Weber; Ebru Erbay
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-30       Impact factor: 11.205

Review 5.  Review. The endoplasmic reticulum: a target for new anticancer drugs.

Authors:  Jerina Boelens; Sofie Lust; Fritz Offner; Marc E Bracke; Barbara W Vanhoecke
Journal:  In Vivo       Date:  2007 Mar-Apr       Impact factor: 2.155

6.  Inhibition of K+ channels and stimulation of insulin secretion by the sulfonylurea, glimepiride, in relation to its membrane binding in pancreatic islets.

Authors:  M Schwanstecher; K Mnner; U Panten
Journal:  Pharmacology       Date:  1994-08       Impact factor: 2.547

7.  Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion.

Authors:  Xueyan Wang; Phuong Le; Congxin Liang; Julie Chan; David Kiewlich; Todd Miller; Dave Harris; Li Sun; Audie Rice; Stefan Vasile; Robert A Blake; Anthony R Howlett; Neela Patel; Gerald McMahon; Kenneth E Lipson
Journal:  Mol Cancer Ther       Date:  2003-11       Impact factor: 6.261

Review 8.  Melanoma and the Unfolded Protein Response.

Authors:  Erin K Sykes; Swetlana Mactier; Richard I Christopherson
Journal:  Cancers (Basel)       Date:  2016-02-27       Impact factor: 6.639

9.  A novel chemical, STF-083010, reverses tamoxifen-related drug resistance in breast cancer by inhibiting IRE1/XBP1.

Authors:  Jie Ming; Shengnan Ruan; Mengyi Wang; Dan Ye; Ningning Fan; Qingyu Meng; Bo Tian; Tao Huang
Journal:  Oncotarget       Date:  2015-12-01

10.  Effect of exenatide, sitagliptin, or glimepiride on β-cell secretory capacity in early type 2 diabetes.

Authors:  Lalitha Gudipaty; Nora K Rosenfeld; Carissa S Fuller; Robert Gallop; Mark H Schutta; Michael R Rickels
Journal:  Diabetes Care       Date:  2014-06-26       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.